Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Results Disclaimer: Individual results vary based on numerous factors including age, baseline health, adherence, lifestyle, genetics, and other variables
In a phase 2 clinical trial for obesity, 26 weeks of efinopegdutide (doses 5 to 10mg) resulted in up to 11.8% WL in people with obesity (without diabetes) compared to 7.5% WL with liraglutide 3 mg and 1.8% WL with placebo [77, 78]
In addition, we have a library of information you can refer to if you ever have any questions
Completely different body composition, metabolic health, and appearance
Mazdutide leads in overall clinical evidence maturity with Phase 3 completion, regulatory approval, and head-to-head superiority data versus semaglutide
References UCL
US$ 21.31
US$ 28.50
US$ 25.57
US$ 24.79
US$ 24.89
US$ 21.51
